Bio Green Med Solution Inc - Company Profile
Powered by 
All the sales intelligence you need on Bio Green Med Solution Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Bio Green Med Solution Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Bio Green Med Solution Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Bio Green Med Solution Catalyst Calendar
Proactively evaluate Bio Green Med Solution Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Bio Green Med Solution Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 31 Dec 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 20 Jun 2020 | Phase I/II Trial Completion | Cyclacel Pharmaceuticals Inc; University of Texas MD Anderson Cancer Center | CYCC | sapacitabine | Oncology | Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia | Clinical Trial Registry |
| 31 Dec 2019 | Phase I Trial Results | Cyclacel Pharmaceuticals Inc; University of Texas MD Anderson Cancer Center | CYCC | CYC-140 | Oncology | Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia); Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Bile Duct Cancer (Cholangiocarcinoma) ; Blood Cancer; Chronic Lymphocytic Leukemia (CLL); Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia); Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Leukemia; Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed Acute Myeloid Leukemia | Company Press Release |
| 01 Dec 2019 | Phase I Trial Initiation | Cyclacel Pharmaceuticals Inc | CYCC | sapacitabine | Oncology | Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Myelodysplastic Syndrome | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer